Q3 2022 Results

Company overview Financial performance Cardiovascular Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Neuroscience Oncology Promacta® - Thrombopoetin receptor agonist NCT03025698 ESCALATE (CETB115E2201) Refractory or relapsed severe aplastic anemia Indication Phase Phase 2 Patients 51 Primary Outcome Measures Arms PK of eltrombopag at steady state in pediatric patients with SAA References Abbreviations Other Promacta® - Thrombopoetin receptor agonist NCT03988608 (CETB115E2202) Indication Refractory or relapsed severe aplastic anemia Hematologic response rate rate up to 26 weeks of treatment Phase Phase 2 Patients 20 Primary Outcome Measures Arms Intervention Intervention Target Patients Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS Arm A: relapsed/refractory SAA or recurrent AA following IST for SAA: hATG/cyclosporine + eltrombopag or cyclosporine + eltrombopag Arm B: previously untreated SAA: hATG/cyclosporine + eltrombopag Pediatric patients from age 1 <18 years with relapsed/refractory SAA or recurrent AA after IST or previously untreated SAA Primary CSR: 2022 Read-out Milestone(s) Publication Final CSR: 2025 Abstract submitted to 64th ASH Annual Meeting and Exposition. 'Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial' Target Patients Read-out Milestone(s) Eltrombopag 25 mg film-coated tablets Chinese patients with refractory or relapsed severe aplastic anemia Primary CSR: 2021 Interim CSR: 2022 Final CSR:2025 Publication TBD 75 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation